- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04308135
Differences Between Patients With Vascular Parkinsonism and Parkinson's Disease
The Clinical and Neuroimaging Differences Between Patients With Vascular Parkinsonism and Idiopathic Parkinson's Disease
Vascular parkinsonism (VP) is defined as the presence of parkinsonian syndrome, evidence of cerebrovascular disease by brain imaging and an established relationship between the two disorders.
However, the diagnosis of VP is problematic. This study aims to distinguish VP from Parkinson's disease (PD) in multiple aspects including clinical features as motor ,non motor symptoms
,response to treatment ,cognitive assessments by using multiple scales, neuro-radiological features of magnetic resonance imaging (MRI) and transcranial color-coded duplex (TCCD) findings. This differentiation will have therapeutic and prognostic implications .
Study Overview
Status
Conditions
Intervention / Treatment
- Diagnostic test: Neuro-radiological tools:
- Diagnostic test: cognitive tests
- Diagnostic test: lab investigations
- Diagnostic test: Beck depression inventory (BDI)(Arabic version)
- Diagnostic test: Clinical Tools for Urinary symptoms:
- Diagnostic test: Freezing of gait questionnaire
- Diagnostic test: non-motor symptoms scales (NMSS).
- Diagnostic test: Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):
- Diagnostic test: ELIZA for alpha-synuclein
- Other: transcranial color-coded duplex(TCCD)
- Other: extracranial carotid duplex
- Other: The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)
Detailed Description
Type of Study : case -control comparative study.
• Study Setting: Patients with VP and patients with PD from movement disorders and stroke outpatient clinics in Ain shams University Hospitals.
Sampling Method study of consecutive patients in Ain Shams University clinic, who had been regularly followed up in the clinic and already had a diagnosis either VP or PD at the time of data collection.
Sample Size: 30 patients diagnosed as VP, 50 patients diagnosed as PD, and 30 healthy age and sex matched controls. The difference in selected quantitative variables used to evaluate the participants is used to estimate the sample size.
This study aims to distinguish VP from Parkinson's disease(PD) in multiple aspects including clinical features as motor ,non-motor symptoms, response to treatment ,cognitive assessments by using multiple scales, neuro-radiological features of magnetic resonance imaging (MRI) and transcranial color-coded duplex(TCCD)findings.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Ain shams university
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
The investigators will recruit 30 patients diagnosed as VP, 50 patients diagnosed as PD
, and 30 healthy age and sex matched controls.
Description
Inclusion Criteria:
- Patients diagnosed with PD or VP, and healthy controls will be included in the study.
- PD diagnosis will be based on the Queen Square Brain Bank for Neurological Disorders clinical criteria and MDS criteria.
- The VP patients will be included if they fulfill the following criteria (Zijlman's diagnostic criteria)Parkinsonism presentation (at least two of the cardinal features: tremors, bradykinesia, rigidity and postural instability).
Cerebrovascular disease, defined as evidence of relevant cerebrovascular disease by brain imaging or the presence of focal signs or symptoms consistent with stroke.
A relationship between (1) and (2): acute or delayed progressive onset of parkinsonism.
Based on the above criteria, two forms of VP are suggested: one with acute onset, and another one with insidious progression. The diagnosis will be confirmed by assigning a vascular score. Two points or more are essential to diagnose VP. The points will be assigned as follows:
- Two points: Pathologically or angiographically proven diffuse vascular disease.
- One point: Onset of parkinsonism within 1 month of clinical stroke.
- One point: History of two or more strokes.
- One point: Neuroimaging evidence of vascular disease in two or more vascular territories.
- One point: History of two or more risk factors for stroke (hypertension, smoking, diabetes mellitus, hyperlipidaemia, presence of heart disease associated with stroke [coronary artery disease, atrial fibrillation, congestive heart failure, valvular heart disease, mitral valve prolapse, and other arrhythmias], family history of stroke, history of gout, and peripheral vascular disease)
Exclusion Criteria:
- PD patients with age at onset less than 40 years.
- Any alternative cause that significantly impair gait.
- Inability of the patient to undergo neuroimaging.
- Patients couldn't perform the test or severely demented.
- Atypical and other secondary parkinsonism as patients who had a history of toxin exposure.or antipsychotic drugs treatment by history ,neurological examination and brain MRI .
- Family or patient's refusal to give written consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
vascular parkinsonism
the investigators will recruit 30 patients diagnosed as Vascular Parkisonism ,
|
MRI brain: to measure white matter c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected.
Other Names:
All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset , and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale
Each patient will undergo full lab investigations:[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes]
Clinical Tool for depression
the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
Clinical Tools for Gait (in on and off state ), Gait will be assessed by:
Clinical Tool for assessment of non-motor symptoms of PD
Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during "OFF" and "ON" states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales. Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS
measuring serum of alpha-synuclein, tau and their autoantibodoies
TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
to assess atherosclerosis, stenosis of carotids
Clinical tool for quality of life of PD patients
|
Parkinson's disease
50 patients diagnosed as Parkinson Disease
|
MRI brain: to measure white matter c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected.
Other Names:
All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset , and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale
Each patient will undergo full lab investigations:[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes]
Clinical Tool for depression
the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
Clinical Tools for Gait (in on and off state ), Gait will be assessed by:
Clinical Tool for assessment of non-motor symptoms of PD
Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during "OFF" and "ON" states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales. Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS
measuring serum of alpha-synuclein, tau and their autoantibodoies
TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
to assess atherosclerosis, stenosis of carotids
Clinical tool for quality of life of PD patients
|
Controls
30 healthy controls.
|
All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset , and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale
Clinical Tool for depression
the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
Clinical Tools for Gait (in on and off state ), Gait will be assessed by:
Clinical Tool for assessment of non-motor symptoms of PD
Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during "OFF" and "ON" states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales. Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS
TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
to assess atherosclerosis, stenosis of carotids
Clinical tool for quality of life of PD patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MDS-UPDRS scale on on and off state
Time Frame: 2 year... will be at single point
|
It detects the motor differences between Vascular Parkinsonism and Parkinson's Disease by scores on the scale ...the maxium score is 199 represents the worst (total disability) with a score of zero representing (no disability)
|
2 year... will be at single point
|
Montreal Cognitive Assessment (MoCA) (Arabic version)
Time Frame: 2 years....will be at single point
|
MoCA scores range between 0 and 30.
.high
score more than or equal 26 is normal
|
2 years....will be at single point
|
White matter severity by MRI brain
Time Frame: 2 years....will be at single point
|
White matter differences by fazekas scale 0,1,2 or 3 scores
|
2 years....will be at single point
|
Non motor symptoms scale
Time Frame: 2 years.....will be at single point
|
It detects the non motor symptoms differences between Vascular Parkinsonism and Parkinson's Disease byUsing a distribution of NMSS scores by quartiles, a classification based on levels from 0 (no NMS at all) to 4 (very severe NMS) for 30 itemes ...high score is worst
|
2 years.....will be at single point
|
Addenbrooke's test (Arabic version)
Time Frame: 2 year ....will be at single point
|
for aassement of Visuospatial skills, Language and verbal fluency result score 16 for visuospatial processing ,26 for language 14 for fluency high score is best
|
2 year ....will be at single point
|
Wechsler Adult Intelligence Scale (WAIS)
Time Frame: 2 year....will be at single point
|
The average score for the test is 100, and any score from 90 to 109 is considered to be in the average intelligence range.
Score from 110 to 119 are considered to be High Average.
Superior scores range from 120 to 129 and anything over 130 is considered Very Superior.
|
2 year....will be at single point
|
Frontal Assessment Battery scale.
Time Frame: 2 year ....will be at single point
|
Frontal Assessment Battery scale..total score is from a maximum of 18, higher scores indicating better performance.
|
2 year ....will be at single point
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Substantia nigra Echogenicity by transcranial doppler
Time Frame: 2 years
|
to detect differences of substantia nigra Echogenicity by millimeter and differences of mean flow velocities by centimeter per second
|
2 years
|
Carotid arties wall thickness by Extra cranial duplex
Time Frame: 2 year
|
to detect differences of Intima-media thickness values by millimeter and flow velocities by centimeter per second
|
2 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MD209/2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on Neuro-radiological tools:
-
Nantes University HospitalCompletedBrain Tumor | Post-operative Complications | Neuro-surgery | Neuro-ICU StayFrance
-
Oticon MedicalCompleted
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
University Hospital, ToulouseCompleted
-
Centre Hospitalier Universitaire, AmiensCompletedStroke | Venous Thromboses | Superior Sagittal Sinus ThrombosisFrance
-
Postgraduate Institute of Medical Education and...CompletedTuberculosis | Tuberculosis; Abdomen (Etiology) | Tuberculosis, PeritonealIndia
-
Jai ShankarUnknownPseudotumor CerebriCanada
-
Aga Khan UniversityJinnah Postgraduate Medical CentreRecruitingNeurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients (PBT)Blood Cancer | Brain Tumor, PediatricPakistan
-
Centre for Orthopaedic Research AlkmaarNoordwest ZiekenhuisgroepRecruiting
-
AO Clinical Investigation and Publishing DocumentationCompletedSpinal Fractures | Spinal Injuries | Spinal Deformity | KyphosisUnited Kingdom, China, Egypt, India, Korea, Republic of